Bibliography
- Rossler W, Salize HJ, Van OJ, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005;15(4):399-409
- Mueser KT, Mcgurk SR. Schizophrenia. Lancet 2004;363:2036-72
- Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008;33(9):2061-79
- Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000;14(4):409-18
- Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41
- Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100(1-3):20-38
- Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009;438:7-14
- Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166(2):152-63
- Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56(3):241-7
- Lieberman JA, Stroup TS, Mcevoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
- Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(Suppl 11):53-60
- Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993;54(Suppl):13-7
- Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand 2007;115(2):93-100
- Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 2007;115(1):4-11
- Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007;64(10):1115-22
- Stover EL, Brady L, Marder SR. New paradigms for treatment development. Schizophr Bull 2007;33(5):1093-9
- Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33(5):1120-30
- Casey DE. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 2006;11(7 Suppl 7):25-31
- Walters J, Jones I. Clinical questions and uncertainty–prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol 2008;22(2 Suppl):82-9
- Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007;61(8):1356-70
- Burton S. Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol 2006;20(6 Suppl):6-19
- Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 2007;11(9):1189-206
- Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 2009;6(1):78-85
- Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 2007;9(4):329-36
- Agid O, Kapur S, Remington G. Emerging drugs for schizophrenia. Expert Opin Emerg Drugs 2008;13(3):479-95
- Masri B, Salahpour A, Didriksen M, et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 2008;105(36):13656-61
- Webber MA, Marder SR. Better pharmacotherapy for schizophrenia: what does the future hold? Curr Psychiatry Rep 2008;10(4):352-8
- Alves FDAS, Figee M, Vamelsvoort T, et al. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol Bull 2008;41(1):121-32
- Kirsch P, Ronshausen S, Mier D, Gallhofer B. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. Pharmacopsychiatry 2007;40(5):196-8
- Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005;6(12):2091-101
- Tadori Y, Kitagawa H, Forbes RA, et al. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol 2007;574(2-3):103-11
- Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007;12(10):904-22
- Corrigan MH, Gallen CC, Bonura ML, Merchant KM. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry 2004;55(5):445-51
- Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999;21(2 Suppl):106S-15S
- Remington G. Alterations of dopamine and serotonin transmission in schizophrenia. Prog Brain Res 2008;172:117-40
- De Paulis T. M-100907 (Aventis). Curr Opin Investig Drugs 2001;2(1):123-32
- Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1159-72
- Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007;113(2):296-320
- Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev 1997;23(1-2):28-46
- Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 2006;31(6):369-76
- Jones CK, Brady AE, Davis AA, et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 2008;28(41):10422-33
- Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9(11):984-97, 979
- Marino MJ, Conn PJ. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord 2002;1(1):1-16
- Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review. J Psychopharmacol 2007;21(4):440-52
- Harrison P, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 2003;1(361):417-9
- Krivoy A, Fischel T, Weizman A. The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur Neuropsychopharmacol 2008;18(6):395-405
- Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2009;30(1):25-31
- Sodhi M, Wood KH, Meador-Woodruff J. Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Rev Neurother 2008;8(9):1389-406
- Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001;25(3):402-9
- Millan MJ, Brocco M, Rivet JM, et al. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents. J Pharmacol Exp Ther 2000;292(1):54-66
- Marcus MM, Jardemark KE, Wadenberg ML, et al. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 2005;8(3):315-27
- Shahid M, Walker G, Zorn S, Wong E. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23(1):65-73
- Ghanbari R, El MM, Shahid M, Blier P. Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur Neuropsychopharmacol 2009;19(3):177-87
- Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63(5):413-20
- Franberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196(3):417-29
- Tait DS, Marston HM, Shahid M, Brown VJ. Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacology (Berl) 2009;202(1-3):295-306
- Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68(10):1492-500
- Potkin SG, Kane JM, Emsley R, et al. Asenapine in Schizophrenia: an Overview of Clinical Trials in the Olympia Program. Collegium Internationale Neuro-Psychopharmacologicum 26th Congress. US Psychiatric and Mental Health Congress, San Diego, Oct 30 - Nov 2 2008
- Emsley R, Schoemaker JH, Vrijland P, et al. Long-Term Safety of Asenapine Versus Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder. U.S. Psychiatric and Mental Health Congress. US Psychiatric and Mental Health Congress, San Diego, Oct 30 – Nov 2 2008
- Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. Eur Psychiatry 2001;16(7):418-23
- Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007;8(7):539-54
- Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002;1(2):141-7
- Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 2008;200(3):317-31
- Barbato LM, Potkin SG, Heisterberg J, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Bifeprunox, a Partial Dopamine D2 Receptor Agonist, in Patients With Acute Exacerbations of Schizophrenia. ACNP, Hollywood, Florida, Dec 2006
- Rapaport M, Barbato LM, Heisterberg J, et al. Efficacy and Safety of Bifeprunox versus Placebo in the Treatment of Patients with Acute Exacerbations of Schizophrenia. Neuropsychopharmacology 2006;31(S1):S184
- Bourin M, Casey DE, Debelle M, et al. Long-term efficacy and safety of bifeprunox for prolongation of time to deterioration in patients with stable schizophrenia: Results from a 6-month, randomized, double-blind, placebo-controlled study. Biol Psychiatry 2007;61(8):249
- Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs 2008;17(1):61-75
- Szewczak MR, Corbett R, Rush DK, et el. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 1995;274(3):1404-13
- Strupczewski JT, Bordeau KJ, Chiang Y, et al. 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem 1995;38(7):1119-31
- Sainati SM, Hubbard JW, Chi E, et al. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol 1995;35(7):713-20
- Kongsamut S, Roehr JE, Cai J, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996;317(2-3):417-23
- Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28(2 Suppl 1):S4-11
- Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-9
- Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8
- Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35
- Andreasen NC, Carpenter WT JR, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162(3):441-9
- Van Beijsterveldt LE, Geerts RJ, Leysen JE, et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 1994;114(1):53-62
- Kramer M, Litman RE, Lane R, et al. Efficacy and tolerability of paliperidone palmitate: 9-week, placebo-controlled study in schizophrenia patients. Biol Psychiatry 2008;63(7):908
- Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Biol Psychiatry 2008;63(7):901
- Gopal S, Lindenmayer JP, Hough D, et al. Safety and tolerability of the investigational antipsychotic paliperidone palmitate injected in the deltoid or gluteus muscle in patients with schizophrenia. Biol Psychiatry 2008;63(7):900
- McEvoy JP. Much ado about small differences. World Psychaitry 2009;8(1):29-30
- Tyrer P, Kendall T. The spurious advance of antipsychotic drug therapy. Lancet 2009;373(9657):31-41
- Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68(16):2269-92
- Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10(1):79-104
- Cahn W, Hulshoff Pol HE, Bongers M, et al. Brain morphology in antipsychotic-naive schizophrenia: a study of multiple brain structures. Br J Psychiatry Suppl 2002;43:s66-72